依普利酮饭前还是饭后服用？

(Inspra) was first approved for marketing in the United States in 2002. It is mainly used clinically to treat hypertension. In 2003, it was approved by the FDA for the treatment of heart failure after acute myocardial infarction. Eplerenone has almost no sex hormone-related side effects of spironolactone, has good therapeutic effect and high safety, and is a good alternative to spironolactone.

Although eplerenone has been on the market in the United States for more than ten years, it has not yet been approved in our country. Therefore, many domestic patients who need medication do not know how to use it. The following medical companions will briefly introduce it to you.

The initial dose of eplerenone (Inspra) for the treatment of congestive heart failure is 25 mg orally once daily; increase to target dose within four weeks as tolerated by the patient. The target dose is 50 mg orally once daily. It can be taken before or after meals. If the patient has special circumstances, the medication should be taken under the advice of a doctor.

When treating adult patients with hypertension, eplerenone (Inspra) can be used alone or in combination with other antihypertensive drugs. It is administered orally. The initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose. Typically, significant blood pressure lowering effects occur within four weeks of taking eplerenone (Inspra). Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Untreated hypertension and heart failure are both associated with adverse pregnancy outcomes. The use of mineralocorticoid receptor antagonists is not recommended for the treatment of chronic isolated hypertension in pregnant women and should generally be avoided in women of reproductive potential.

Patients need to be closely monitored for hyperkalemia during treatment. The risk of hyperkalemia increases with renal impairment, proteinuria, diabetes mellitus, and in patients taking concomitant ACE (angiotensin-converting enzyme) inhibitors, angiotensin II inhibitors, nonsteroidal anti-inflammatory drugs, or moderate CYP3A inhibitors. As hyperkalemia develops, dose reduction or treatment interruption may be necessary.

Recommended related hot articles: /newsDetail/72959.html